Antioxidants: The Missing Key to Improved Therapeutic Intervention in Smith-Lemli-Opitz Syndrome
Steven J Fliesler *
VA Western New York Healthcare System; Departments of Ophthalmology and Biochemistry, State University of New York- University at Buffalo; and the SUNY Eye Institute, Buffalo, New York, USA
- *Corresponding Author:
- Steven J. Fliesler, PhD
Research Service, VAWNYHS (Buffalo VAMC)
3495 Bailey Avenue- Mail Stop 151
Buffalo, NY 14215-1129, USA
E-mail: [email protected]
Received Date: October 28, 2013; Accepted Date: November 28, 2013; Published Date: November 30, 2013
Citation: Fliesler SJ (2013) Antioxidants: The Missing Key to Improved Therapeutic Intervention in Smith-Lemli-Opitz Syndrome? Genetics 2:119. doi: 10.4172/2161-1041.1000119
Copyright: © 2013 Fliesler SJ. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Smith-Lemli-Opitz Syndrome (SLOS) is a recessive hereditary disease caused by an enzymatic defect in the biosynthesis of cholesterol. To date, the therapeutic standard of care for this disease has been cholesterol supplementation therapy. However, the efficacy of this treatment is extremely variable and, in many if not most cases, is poor. Results of studies using animal models of SLOS have suggested that cholesterol deficiency and/or the aberrant accumulation of the immediate precursor of cholesterol (7-dehydrocholesterol (7DHC)), per se, may not be the sole culprits in the pathobiology of this disease. Rather, cytotoxic oxysterol by-products derived specifically from 7DHC are thought to be additional, significant, causative players in the disease mechanism. Based in large measure upon such studies, a recent clinical trial, comparing the therapeutic efficacy of cholesterol supplementation alone vs. combined cholesterol-antioxidant supplementation in SLOS patients, has provided extremely encouraging results that tend to both validate the proposed role of oxysterols in the pathobiology of SLOS as well as indicate an improved treatment for this and related diseases.